New Horizons for Diffuse Large B-Cell Lymphoma
Recent advancements in treatment options for patients with diffuse large B-cell lymphoma have been practice-changing.
‘Pivotal’ Time for DLBCL Treatment Options
The Food and Drug Administration, in a flurry of activity, approved three new medications across a three-month period earlier this year.
Minimal Residual Disease Remains An Evolving and Game-Changing Field
MRD testing began among patients with chronic myeloid leukemia, a disease that lends itself to gauging MRD because it is driven by a specific genetic mutation.
On the Lookout for Minimal Residual Disease in Leukemia
Why minimal residual disease testing is the "gold standard" for some patients and providers.
